Navigation Links
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Date:9/21/2009

re reduced or delayed. The primary and secondary endpoints of the denosumab bone metastases studies use a composite endpoint of four SREs - fracture, the need for radiation to bone, the need for bone surgery, and spinal cord compression - to measure the effectiveness of denosumab versus Zometa.

The primary endpoint was to evaluate if denosumab is non-inferior to Zometa with respect to the first on-study SRE in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma and bone metastases. Secondary endpoints were to evaluate if denosumab is superior to Zometa with respect to the first on-study SRE, as well as first-and-subsequent on-study SREs, and to assess the safety and tolerability of denosumab compared with Zometa.

About Denosumab and Amgen's Research in Bone Biology

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, the essential regulator of osteoclasts (the cells that break down bone). With more than 19,000 patients in trials across indications worldwide, the denosumab development program is the largest ever initiated by Amgen. This broad and deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs. Amgen is studying denosumab in numerous tumor types across the spectrum of cancer-induced bone disease. Over 11,000 patients have been enrolled in the denosumab oncology clinical trials, testing the drug for the reduction of SREs in breast cancer patients, for the amelioration of treatment-induced bone loss in patients with breast or prostate cancers, for the prevention of SREs due to the spread of cancer to the bone in patients with multiple myeloma or those suffering from a variety of solid tumors, and for its potential to delay bone metastases in prostate cancer.

Bone Metastases: Impact and Pre
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical ... infections, today announced that it has initiated dosing in ... once daily, oral therapy for the treatment of HCV ... and is designed to assess both the safety and ... first-in-class drug for the treatment of chronic HCV infections ...
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
(Date:5/23/2013)... , May 23, 2013 Halozyme Therapeutics, ... the appointment of David A. Ramsay ... was most recently Vice President, Corporate Development at ... "With his established financial management experience ... by working in our commercial group for the ...
Breaking Medicine Technology:Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2
... (Nasdaq: KNDL ), a leading, global full-service ... its Annual Meeting of Shareholders due to its merger ... been scheduled for May 19, 2011, in Cincinnati, Ohio. ... a merger agreement with INC Research.  The merger transaction ...
... A new device designed to assist blood circulation ... coronary intervention (PCI) has shown improved outcomes compared to ... of the PROTECT II study were presented as a ... Sessions in Baltimore. These devices decrease ...
Cached Medicine Technology:Kendle Announces Postponement of 2011 Annual Meeting 2Kendle Announces Postponement of 2011 Annual Meeting 3Kendle Announces Postponement of 2011 Annual Meeting 4New Device to Support Blood Circulation for Heart Patients Shows Improved Outcomes Compared to Current Treatment 2
(Date:5/24/2013)... The leading retail brand Short Dresses ... prom dresses . Now that is quite unbelievable, especially in ... brand name since its origin. The retailer has already revealed ... this huge discount offer will be an added bonanza for ... privileged to announce that Short Dresses is to offer different ...
(Date:5/23/2013)... NY (PRWEB) May 24, 2013 Magnatag’s ... employee absentee patterns and reduces vacation conflicts. A Manufacturing ... problem with vacation conflicts; now employees and managers can ... have any problems. Attendance is important to us and ... are exposed. That may seem harsh but it has ...
(Date:5/23/2013)... May 24, 2013 Sublime Beauty® ... Cellulite Whisperer line, with a 35% discount ... Sale" includes two proprietary products, the Cellulite ... . , Purchasers receive a report "Getting Control ... Gel has a wonderful grapefruit scent," says Kathy ...
(Date:5/23/2013)... -- High blood glucose is associated with poor outcomes ... (IIT) to control hyperglycemia is a common practice in ... consistent benefit and even shows harms associated with the ... Physicians, (ACP) Clinical Guidelines Committee in a new evidence-based ... of Medical Quality . , "Clinicians caring for hospitalized ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Whether working ... Operations Forces and law enforcement need an added layer ... Security Enhancer, Night VISER , is an effective ... motion sensing system to increase border and perimeter security. ... VISER have more than tripled over the past three ...
Breaking Medicine News(10 mins):Health News:short prom dresses Offers Abnormally Low Discount on Its New Collections 2Health News:New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance 2Health News:Fresh Organics in the New Cellulite Whisperer® Products from Sublime Beauty®; "Get Ready for Summer Sale" Continues 2Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3
... , This release is available in German . ... encoding data at a rate of 26 terabits per second on ... km, and decoding them successfully. This is the largest data volume ... allows to transmit the contents of 700 DVDs in one second ...
... Mount Sinai School of Medicine have discovered a protein signaling ... medications to inhibit this pathway may be effective in the ... the current issue of the journal Cancer Cell . ... Jack and Jane B. Aron Professor and Chairman of the ...
... a number from the University of North Carolina at Chapel ... that contribute to the debilitating lung disease that is the ... into the causes of the wide variation in lung disease ... to new diagnostic markers and therapeutic approaches for this and ...
... , SUNDAY, May 22 (HealthDay News) -- New Swedish ... of major cardiovascular complications among patients who have ... finding builds on earlier work that was published by ... fall. That study suggested that Inspra (eplerenone), an aldosterone ...
... has found that allowing full access to personal medical ... cancer patients. Published early online in Cancer , ... study indicates that providing accurate information to patients through ... communication with their physicians. Most cancer patients say ...
... Hospital for Special Surgery in New York has shown that ... suppress aspects of inflammation. The researchers say the identification of ... new treatments for diseases such as rheumatoid arthritis. The study ... the journal Nature Immunology . "Prior to this ...
Cached Medicine News:Health News:World record in ultra-rapid data transmission 2Health News:Mount Sinai researchers discover possible new target for sarcoma treatment and prevention 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 3Health News:Blood Pressure Drug Helps Those With Mild Heart Failure 2Health News:Access to personal medical records increases satisfaction among new cancer patients 2Health News:Study identifies novel role for a protein that could lead to new treatments for rheumatoid arthritis 2Health News:Study identifies novel role for a protein that could lead to new treatments for rheumatoid arthritis 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: